Loading market dashboard
Unicycive Therapeutics, Inc.
UNCYHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026. Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence.
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update.
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET.
LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update.
Unicycive Therapeutics, Inc. (NASDAQ: UNCY - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among brokers
